Log In
BCIQ
Print this Print this
 

OS2966

  Manage Alerts
Collapse Summary General Information
Company OncoSynergy Inc.
DescriptionHumanized mAb against integrin beta(1) (CD29)
Molecular Target Integrin beta(1) (CD29)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/05/2016

Undisclosed

Undisclosed

0

Get a free BioCentury trial today